Novavax Shares Decline Amid Broader Market Volatility
At 11:34 PM Central European Time on Friday, November 23, 2026, the share price of Novavax, Inc. (ticker NVAX) fell by 9.26 % over the preceding 24‑hour trading interval. The current market price sits around USD 9.70 per share on the Nasdaq, with a total float of 164.9 million shares outstanding. This valuation translates to a market capitalization of approximately USD 1.80 billion. In the last 24 hours, roughly USD 121.9 million worth of shares were exchanged, indicating a moderate level of liquidity for the stock.
Technical Overview
The price trajectory for Novavax has been in a downward trend since the close of last month, with a cumulative decline of 5.31 %. The 200‑day simple moving average (SMA) currently sits at USD 9.23, meaning the share is trading above its long‑term average. Over the past year, the stock’s highest point reached USD 13.39 on May 10, 2026, while the low was USD 6.20 on November 20, 2025, suggesting a broad 52‑week range of USD 7.19.
Comparative Performance of Peer Stocks
| Stock | 24‑hour change | Current price | Market cap (USD bn) | P/E |
|---|---|---|---|---|
| Gigacloud (GCT) | +2.48 % | USD 58.24 | 2.2 | 14.31 |
| Proto Labs (PRLB) | –5.94 % | USD 85.61 | 2.2 | 71.49 |
| Progyny (PGNY) | –0.49 % | USD 28.97 | 2.2 | 30.91 |
| Alamar Biosciences (ALMR) | +11.68 % | USD 30.65 | 2.2 | – |
| Recursion (RXRX) | –0.55 % | USD 3.70 | 2.2 | – |
While Novavax’s decline is the most pronounced among these comparables, the broader sector exhibits a mixture of modest gains and losses. Gigacloud’s positive movement and Alamar’s significant rise reflect sector‑specific catalysts, whereas Proto Labs and Recursion experienced similar, albeit smaller, downturns.
Recent Corporate Developments
Alamar Biosciences disclosed a series of share‑sale transactions on October 19 and 20, 2026, involving Qiming‑affiliated investment vehicles. These transactions were executed at weighted average prices within narrow ranges and increased holdings for the largest participant to over 6.7 million shares, with smaller sales leaving other investors in the hundreds of thousands. While the transactions did not immediately alter the share price dramatically, they provide a clearer view of ownership concentration and voting influence within the company.
Novavax’s Strategic Position
Novavax, Inc. is a clinical‑stage biotechnology firm headquartered in Gaithersburg, United States. The company leverages proprietary virus‑like particle (VLP) technology to develop novel vaccines aimed at a broad spectrum of infectious diseases. Since its public listing on the Nasdaq in December 1995, Novavax has positioned itself as a potential disruptor in the vaccine industry, focusing on both pandemic preparedness and routine immunization. Investors and analysts will likely monitor the company’s ongoing clinical trials, regulatory milestones, and commercial partnerships for signals that could influence the stock’s trajectory in the coming months.